Vilsboll T, Krarup T, Madsbad S, Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
CVOTs have shown that GLP-1 receptor agonists reduce MACE in patients with T2D compared to placebo
The increased risk may relate to rapid weight loss, changes in gallbladder motility, or alterations in bile acid composition
How long will it take before I see results
If youre researching retatrutide for a lab protocol, the calculator removes the manual math of reconstitution, concentration, and dose conversion but it only gives you a correct number if you understand what each input actually represents
Diabetes 2023;72(Supplement 1):51OR